Valion Bio Inc (VBIO : NASDAQ)
Common Stock
$3.48
USD
+0.75 (27.47%)
Last updated: 2026-09-24
Follow VBIO
VBIO
Valion Bio Inc
WealthAwesomePerformance
1 Day
+27.47%
1 Week
+56.05%
1 Month
-12.45%
YTD
-75.54%
Key Statistics
Market Cap
$2.42M
52W High
$78.75
52W Low
$2.05
P/E Ratio
-
50 Day MA
$5.14
200 Day MA
$20.75
Beta
1.79
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/24/2026 | $2.62 | $3.79 | $2.32 | $3.48 | $3.48 | 10,530,998 |
| 9/23/2026 | $2.45 | $3.29 | $2.25 | $2.73 | $2.73 | 2,083,155 |
| 9/22/2026 | $2.41 | $2.80 | $2.36 | $2.49 | $2.49 | 520,318 |
| 9/21/2026 | $2.14 | $2.45 | $2.13 | $2.38 | $2.38 | 120,717 |
| 9/18/2026 | $2.29 | $2.36 | $2.12 | $2.12 | $2.12 | 56,900 |
| 9/17/2026 | $2.16 | $2.44 | $2.12 | $2.23 | $2.23 | 216,252 |
| 9/16/2026 | $2.05 | $2.26 | $2.05 | $2.08 | $2.08 | 111,344 |
| 9/15/2026 | $2.12 | $2.17 | $2.06 | $2.11 | $2.11 | 33,966 |
| 9/14/2026 | $2.25 | $2.42 | $2.10 | $2.10 | $2.10 | 149,597 |
| 9/11/2026 | $2.19 | $2.39 | $2.17 | $2.26 | $2.26 | 161,111 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VBIO's historical volatility
30-Day Vol
202.2%
Annualized
90-Day Vol
170.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$2.91
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$3.28 | US$1.63 – US$6.59 |
| 60 trading days | US$3.09 | US$1.15 – US$8.29 |
| 90 trading days | US$2.91 | US$0.87 – US$9.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Valion Bio Inc
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Financials
- Revenue (TTM)
- $-86,000
- EBITDA
- $-16.54M
- Profit Margin
- 0.00%
- ROE (TTM)
- -459.52%
- EPS (Diluted)
- -204.45
- Book Value
- 25.57
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About VBIO.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| RPGL | Republic Power Group Limited Class A Ordinary Shares | $14.69 | +1363.23% |
| KITT | Nauticus Robotics Inc. | $2.93 | +459.21% |
| ZWZZT | NASDAQ TEST STOCK | $24.50 | +144.51% |
| SRZN | Surrozen Inc | $33.68 | +108.42% |
| GLND | Greenland Energy Company Common Stock | $5.35 | +83.85% |
| PMAX | Powell Max Limited Class A Ordinary Shares | $1.65 | +80.62% |
| STAK | STAK Inc. Ordinary Shares | $1.44 | +53.19% |
| PFSA | Profusa, Inc. Common Stock | $3.03 | +47.80% |